Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Key Takeaways A pill to treat obesity caused liver injury in a clinical trialPfizer said it will stop developing the drug, called danuglipron, as a result Other alternatives to injectable obesity ...

Medications like Ozempic, Wegovy, and Zepbound have helped many Americans lose weight, but there are still some ...

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...

It's probably safe to say that weight-loss drugs aren't going anywhere any time soon. According to the most recent data, six percent of American adults, or roughly 16 million people, take such ...

Mounjaro's launch of a weight-loss drug has sparked interest amongst the people of India despite the high price. Experts believe that making the drug locally available would help to reduce the black ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

While King Charles and Queen Camilla marked their 20th wedding anniversary with a royal tour of Italy, the king's ...